Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

Fig. 1

Daratumumab Re-Treatment Patterns. DPd: daratumumab, pomalidomide, and dexamethasone; DRd: daratumumab, lenalidomide, and dexamethasone; DVd: daratumumab, bortezomib, and dexamethasone. Notes: [1] Other regimens include: bortezomib + daratumumab + dexamethasone + pomalidomide, bortezomib + cyclophosphamide + daratumumab + dexamethasone, carfilzomib + cisplatin + cyclophosphamide + daratumumab + dexamethasone + etoposide, carfilzomib + daratumumab, carfilzomib + daratumumab + pomalidomide, daratumumab + denosumab + pomalidomide + dexamethasone. [2] Other regimens include: bortezomib + daratumumab + dexamethasone + pomalidomide, bortezomib + cyclophosphamide + daratumumab + dexamethasone, carfilzomib + daratumumab, daratumumab + dexamethasone + selinexor, daratumumab + venetoclax, cyclophosphamide + daratumumab + dexamethasone + pomalidomide, carfilzomib + cisplatin + cyclophosphamide + daratumumab + dexamethasone + etoposide + doxorubicin + melphalan + thalidomide, carfilzomib + daratumumab + cyclophosphamide + doxorubicin + etoposide, biaxin + carfilzomib + cisplatin + daratumumab + etoposide + liposomal doxorubicin + venetoclax, DPd + ixazomib.. [3] Other agents include: cisplatin, doxorubicin, bortezomib, ixatuzumab, lenalidomide, thalidomide, selinexor, venetoclax, melphalan, panobinostat, and clinical trial/investigational agents

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us